Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18

  • Kuppala, Manohar Babu (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Syed, Sunayana Begum (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Bandaru, Srinivas (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Varre, Sreedevi (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Akka, Jyothy (Institute of Genetics and Hospital for Genetic Diseases, Osmania University) ;
  • Mundulru, Hema Prasad (Institute of Genetics and Hospital for Genetic Diseases, Osmania University)
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity in preclinical models. It plays pivotal roles in linking inflammatory immune responses and tumor progression and is a useful candidate in gene therapy of lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 (rhIL-18) in patients with advanced cancer concluded that rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. Some viruses can induce the secretion of IL-18 for immune evasion. The individual cytokine activity might be potentiated or inhibited by combinations of cytokines. Here we focus on combinational effects of cytokines with IL-18 in cancer progression. IL-18 is an important non-invasive marker suspected of contributing to metastasis. Serum IL-18 may a useful biological marker as independent prognostic factor of survival. In this review we cover roles of IL-18 in immune evasion, metastasis and angiogenesis, applications for chemotherapy and prognostic or diagnostic significance.

Keywords

References

  1. Alagkiozidis I, Facciabene A, Tsiatas M, et al (2011). Timedependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med, 25, 9-77.
  2. Amin MA, Mansfield PJ, Pakozdi A, et al (2007). IL-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum, 56, 1787-97. https://doi.org/10.1002/art.22705
  3. Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A (2009). Hand neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. J Laryngol Otol, 123, 444-8. https://doi.org/10.1017/S0022215108003733
  4. B Zhang, K-F Wu1, Y-M Lin, et al (2004). 1 Gene transfer of pro-IL-18 and IL-1b converting enzyme cDNA induces potent antitumor effects in L1210 cells. Leukemia, 18, 817-25. https://doi.org/10.1038/sj.leu.2403320
  5. Badiola I, Olaso E, Crende O, Friedman SL, Vidal-Vanaclocha F (2011). Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut.
  6. Bouzgarrou N, Hassen E, Schvoerer E, et al (2008). Association of interleukin-18 polymorphisms and plasma level with the outcome of chronic HCV infection. J Med Virol, 80, 607-14. https://doi.org/10.1002/jmv.21079
  7. Cao Q, Cai W, Niu G, He L, Chen X (2008). Multimodality imaging of IL-18--binding protein-Fc therapy of experimental lung metastasis. Clin Cancer Res, 14, 6137-45. https://doi.org/10.1158/1078-0432.CCR-08-0049
  8. Cao R, Farnebo J, Kurimoto M, Cao Y (1999). IL-18 acts as an angiogenesis and tumor suppressor. FASEB J, 13, 2195-202. https://doi.org/10.1096/fasebj.13.15.2195
  9. Carbone A, Vizio B, Novarino A, et al (2009). IL-18 paradox in pancreatic carcinoma: elevated serum levels of free IL-18 are correlated with poor survival. J Immunother, 32, 920-31. https://doi.org/10.1097/CJI.0b013e3181b29168
  10. Chattergoon MA, Levine JS, Latanich R, et al (2011). High plasma interleukin-18 levels mark the acute phase of hepatitis C virus infection. J Infect Dis, 204, 1730-40. https://doi.org/10.1093/infdis/jir642
  11. Cho D, Song H, Kim YM, et al (2000). Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res, 60, 2703-9.
  12. Cho ML, Jung YO, Moon YM, et al (2006). IL-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways. Immunol Lett, 103, 159-66. https://doi.org/10.1016/j.imlet.2005.10.020
  13. Coughlin CM, Salhany KE, Wysocka M, et al (1998). Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest, 101, 1441-52. https://doi.org/10.1172/JCI1555
  14. Cui G, Yuan A, Goll R, et al (2007). Distinct changes of dendritic cell number and IL-12 mRNA level in adjacent mucosa throughout the colorectal adenoma-carcinoma sequence. Cancer Immunol Immunother, 56, 1993-2001. https://doi.org/10.1007/s00262-007-0345-9
  15. Diakowska D, Markocka-Maczka K, Grabowski K, Lewandowski A (2006). Serum interleukin-12 and interleukin-18 levels in patients with oesophageal squamous cell carcinoma. Exp Oncol, 28, 319-22.
  16. Eissa SA, Zaki SA, El-Maghraby SM, Kadry DY (2005). Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J Egypt Natl Canc Inst, 17, 51-5.
  17. Elaraj DM, Weinreich DM, Varghese S, et al (2006). The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res, 12, 1088-96. https://doi.org/10.1158/1078-0432.CCR-05-1603
  18. Elias AS, et al. 2009, PD-1 Induced IL10 Production by Monocytes Impairs T-cell Activation in a Reversible Fashion. Nature Medicine, 452-9.
  19. Farhat K, Hassen E, Bouzgarrou N, et al (2008). Functional IL-18 promoter gene polymorphisms in Tunisian nasopharyngeal carcinoma patients. Cytokine, 43, 132-7. https://doi.org/10.1016/j.cyto.2008.05.004
  20. Farjadfar A, Mojtahedi Z, Ghayumi MA, et al (2009). Interleukin-18 promoter polymorphism is associated with lung cancer: a case-control study. Acta Oncol, 48, 971-6. https://doi.org/10.1080/02841860902878145
  21. Fujita K, Ewing CM, Isaacs WB, Pavlovich CP (2011). Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. Int J Cancer, 129, 424-32. https://doi.org/10.1002/ijc.25705
  22. Gollob JA, Mier JW, Veenstra K, et al (2000). Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res, 6, 1678-92.
  23. Haghshenas MR, Hosseini SV, Mahmoudi M, Saberi-Firozi M, Farjadian S, Ghaderi A (2009). IL-18 serum level and IL-18 promoter gene polymorphism in Iranian patients with gastrointestinal cancers. J Gastroenterol Hepatol, 24, 1119-22. https://doi.org/10.1111/j.1440-1746.2009.05791.x
  24. Han Ming-yong, Zheng Shu, Yu Jin-ming, et al (2004). Study on interleukin-18 gene transfer into human breast cancer cells to prevent tumorigenicity. J Zhejiang Univ SCI, 5, 472-6. https://doi.org/10.1631/jzus.2004.0472
  25. Ingram JT, Yi JS, Zajac AJ (2011). Exhausted CD8 T cells downregulate the IL-18 receptor and become unresponsive to inflammatory cytokines and bacterial co-infections. PLoS Pathog, 7, 1002273. https://doi.org/10.1371/journal.ppat.1002273
  26. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L (2005). VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine, 30, 93-9. https://doi.org/10.1016/j.cyto.2004.12.004
  27. Jebreel A, Mistry D, Loke D, et al (2007). Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol, 121, 246-52.
  28. Jung MK, Park Y, Song SB, et al (2011). Erythroid differentiation regulator 1, an interleukin 18-regulated gene, acts as a metastasis suppressor in melanoma. J Invest Dermatol, 131, 2096-104. https://doi.org/10.1038/jid.2011.170
  29. Kang JS, Bae SY, Kim HR, et al (2009). Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44. Carcinogenesis, 30, 1987-96. https://doi.org/10.1093/carcin/bgp158
  30. Kaser A, Novick D, Rubinstein M, et al (2002). Tilg interferon-a induces interleukin-18 binding protein in chronic hepatitis C patients. Clin Exp Immunol, 129, 332-8 https://doi.org/10.1046/j.1365-2249.2002.01911.x
  31. Kei-ichi Y, Rachael C, Rebecca D, et al (2006). Kupper1 Expression of Interleukin-18 and Caspase-1in Cutaneous T-Cell Lymphoma. Clin Cancer Res, 12, 2.
  32. Khalili-Azad T, Razmkhah M, Ghiam AF, et al (2009). Association of interleukin-18 gene promoter polymorphisms with breast cancer. Neoplasma, 56, 22-5. https://doi.org/10.4149/neo_2009_01_22
  33. Khatri A, Husaini Y, Ow K, Chapman J, Russell PJ (2009). Cytosine deaminase-uracil phosphoribosyltransferase and interleukin (IL)-12 and IL-18: a multimodal anticancer interface marked by specific modulation in serum cytokines. Clin Cancer Res, 15, 2323-34. https://doi.org/10.1158/1078-0432.CCR-08-2039
  34. Kim J, Kim C, Kim TS, et al (2006). IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway. Biochem Biophys Res Commun, 344, 1284-9. https://doi.org/10.1016/j.bbrc.2006.04.016
  35. Kim J, Shao Y, Kim SY, et al (2008). Hypoxia-induced IL-18 increases hypoxia-inducible factor-1alpha expression through a Rac1-dependent NF-kappaB pathway. Mol Biol Cell, 19, 433-44.
  36. Kim KE, Song H, Hahm C, et al (2009). Expression of ADAM33 is a novel regulatory mechanism in IL-18-secreted process in gastric cancer. J Immunol, 182, 3548-55. https://doi.org/10.4049/jimmunol.0801695
  37. Kim KE, Song H, Kim TS, et al (2007). IL-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene, 26, 1468-76. https://doi.org/10.1038/sj.onc.1209926
  38. Kim YS, Cheong JY, Cho SW, et al (2009). A functional SNP of the Interleukin-18 gene is associated with the presence of hepatocellular carcinoma in hepatitis B virus-infected patients. Dig Dis Sci, 54, 2722-8. https://doi.org/10.1007/s10620-009-0970-6
  39. Kinoshita M, Miyazaki H, Ono S, et al (2011). Enhancement of neutrophil function by interleukin-18 therapy protects burn-injured mice from methicillin-resistant Staphylococcus aureus. Infect Immun, 79, 2670-80. https://doi.org/10.1128/IAI.01298-10
  40. Kuryliszyn-Moskal A, Dubicki A, Zarzycki W, Zonnenberg A, Gorska M (2011). Microvascular abnormalities in capillaroscopy correlate with higher serum IL-18 and sEselectin levels in patients with type 1 diabetes complicated by microangiopathy. Folia Histochem Cytobiol, 49, 104-10. https://doi.org/10.5603/FHC.2011.0015
  41. Ledee N, Petitbarat M, Rahmati M, et al (2011). New preconception immune biomarkers for clinical practice: interleukin-18, interleukin-15 and TWEAK on the endometrial side, G-CSF on the follicular side. J Reprod Immunol, 88, 118-23. https://doi.org/10.1016/j.jri.2011.01.007
  42. Li W, Kubo S, Okuda A, et al (2010). Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J Immunother, 33, 287-96. https://doi.org/10.1097/CJI.0b013e3181c80ffa
  43. Lissoni P, Brivio F, Rovelli F, et al (2000). Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents, 14, 275-7.
  44. Liu Y, Lin N, Huang L, Xu Q, Pang G (2007). Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 26, 613-8. https://doi.org/10.1089/dna.2007.0600
  45. Majima T, Ichikura T, Chochi K, et al (2006). Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer, 118, 388-95. https://doi.org/10.1002/ijc.21334
  46. Majima T, Ichikura T, Seki S, et al (2002). The influence of interleukin-10 and interleukin-18 on interferon-gamma production by peritoneal exudate cells in patients with gastric carcinoma. Anticancer Res, 22, 1193-9.
  47. Michael JR, John MK, Theodore FL, et al (2010). Dar4 A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer. Clin Cancer Res, 14, 11.
  48. Mohran ZY, Ali-Eldin FA, Abdel Aal HA (2011). Serum interleukin-18: does it have a role in the diagnosis of hepatitis C virus related hepatocellular carcinoma? Arab J Gastroenterol, 12, 29-33. https://doi.org/10.1016/j.ajg.2010.11.002
  49. Mojtahedi Z, Khademi B, Hashemi SB, et al (2011). Serum interleukine-6 concentration, but not interleukine-18, is associated with head and neck squamous cell carcinoma progression. Pathol Oncol Res, 17, 7-10. https://doi.org/10.1007/s12253-010-9261-y
  50. Muller J, Feige K, Wunderlin P, et al (2011). Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother, 34, 58-64. https://doi.org/10.1097/CJI.0b013e3181fe1997
  51. Nilkaeo A, Bhuvanath S (2006). Role of interleukin-18 in modulation of oral carcinoma cell proliferation. Mediators Inflamm, 3, 67120.
  52. Nishio S, Yamada N, Ohyama H, et al (2008). Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alphagalactosylceramide and interleukin-18. Cancer Sci, 99, 113-20.
  53. Nong LG, Luo B, Zhang L, Nong HB (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13. https://doi.org/10.1089/dna.2009.0912
  54. Okamoto M, Azuma K, Hoshino T, et al (2009). Correlation of decreased survival and IL-18 in bone metastasis. Intern Med, 48, 763-73. https://doi.org/10.2169/internalmedicine.48.1851
  55. Orengo AM, Fabbi M, Miglietta L, et al (2010). Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor. Int J Cancer.
  56. Page F, Galon J, Galina K, et al (2005). Wolf-Herman Fridman, and Berthold Henglein Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 105, 1632-9. https://doi.org/10.1182/blood-2004-08-3196
  57. Park CC, Morel JC, Amin MA, et al (2001). Evidence of IL-18 as a novel angiogenic mediator. J Immunol, 167, 1644-53. https://doi.org/10.4049/jimmunol.167.3.1644
  58. Park S, Cheon S, Cho D (2007). The dual effects of interleukin-18 in tumor progression. Cell Mol Immunol, 4, 329-35.
  59. Qiao H, Sonoda KH, Ikeda Y, et al (2007). IL-18 regulates pathological intraocular neovascularization. J Leukoc Biol, 81, 1012-21. https://doi.org/10.1189/jlb.0506342
  60. Redlinger RE Jr, Mailliard RB, Lotze MT, Barksdale EM Jr (2003). Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo. J Pediatr Surg, 38, 301-7. https://doi.org/10.1053/jpsu.2003.50098
  61. Robertson MJ, Mier JW, Logan T, et al (2006). Clinical and biological effects of recombinant humaninterleukin-18 administered by intravenous infusion to patients with advanced cancer. Clin Cancer Res, 12, 4265-73. https://doi.org/10.1158/1078-0432.CCR-06-0121
  62. Rovina N, Hillas G, Dima E, et al (2011). VEGF and IL-18 in induced sputum of lung cancer patients. Cytokine, 54, 277-81. https://doi.org/10.1016/j.cyto.2011.02.014
  63. Sabel MS, Su G, Griffith KA, Chang AE (2010). Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer. Breast Cancer Res Treat, 122, 325-36. https://doi.org/10.1007/s10549-009-0570-3
  64. Saenz-Lopez P, Carretero R, Vazquez F, et al (2010). Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol, 71, 309-13. https://doi.org/10.1016/j.humimm.2009.11.010
  65. Salado C, Olaso E, Gallot N, et al (2011). Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J Transl, 9, 59. https://doi.org/10.1186/1479-5876-9-59
  66. Salcedo R, Worschech A, Cardone M, et al (2010).MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med, 207, 1625-36. https://doi.org/10.1084/jem.20100199
  67. Samsami DA, Shahriary K, Kashef MA, et al (2009). Interleukin-18 gene promoter and serum level in women with ovarian cancer. Mol Biol Rep, 36, 2393-7. https://doi.org/10.1007/s11033-009-9469-7
  68. Setsuda J, Teruya-Feldstein J, Harris NL, et al (1999). Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol, 155, 257-65. https://doi.org/10.1016/S0002-9440(10)65119-X
  69. Skopiński P, Rogala E, Duda-Krol B, et al (2005). Increased IL-18 content and angiogenic activity of sera from diabetic (Type 2) patients with background retinopathy. J Diabetes Complications, 19, 335-8. https://doi.org/10.1016/j.jdiacomp.2005.02.008
  70. Sobti RC, Shekari M, Tamandani DM, Malekzadeh K, Suri V (2008). Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res, 17, 159-66. https://doi.org/10.3727/096504008785114156
  71. Song H, Kim J, Lee HK, et al (2011). Selenium inhibits migration of murine melanoma cells via down-modulation of IL-18 expression. Int Immunopharmacol.
  72. Srabovic N, Mujagic Z, Mujanovic-Mustedanagic J, Muminovic Z, Cickusic E (2011). Interleukin 18 expression in the primary breast cancer tumour tissue. Med Glas Ljek komore Zenicko-doboj kantona, 8, 109-15.
  73. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A, Poovorawan Y (2007). Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol, 13, 4345-9. https://doi.org/10.3748/wjg.v13.i32.4345
  74. Tasaki K, Yoshida Y, Maeda T, et al (2000). Protective immunity is induced in murine colon carcinoma cells by the expression of IL-12 orIL-18, which activate type 1 helper T cells. Cancer Gene Ther, 7, 247-54. https://doi.org/10.1038/sj.cgt.7700094
  75. Terme M, Ullrich E, Aymeric L, et al (2011). IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res, 71, 5393-9. https://doi.org/10.1158/0008-5472.CAN-11-0993
  76. Thong-Ngam D, Tangkijvanich P, Lerknimitr R, et al (2006). Diagnostic role of serum interleukin-18 in gastric cancer patients. World J Gastroenterol, 12, 4473-7. https://doi.org/10.3748/wjg.v12.i28.4473
  77. Tsuboi K, Miyazaki T, Nakajima M, et al (2004). Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett, 205, 207-14. https://doi.org/10.1016/j.canlet.2003.10.010
  78. Tsurumi H, Kasahara S, Kanemura N, et al (2011). Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol, 87, 217-27. https://doi.org/10.1111/j.1600-0609.2011.01649.x
  79. Vairaktaris E, Serefoglou ZC, Yapijakis C, et al (2007). The interleukin-18 -607A/C polymorphism is not associated with risk for oral cancer. Anticancer Res, 27, 4011-4.
  80. Volin MV, Koch AE (2011). IL-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res, 31, 745-51. https://doi.org/10.1089/jir.2011.0050
  81. Wang Y, Chaudhri G, Jackson RJ, Karupiah G (2009). IL-12p40 and IL-18 play pivotal roles in orchestrating the cell-mediated immune response to a poxvirus infection. J Immunol, 183, 3324-31 https://doi.org/10.4049/jimmunol.0803985
  82. Wei YS, Lan Y, Liu YG, et al (2007). Interleukin-18 gene promoter polymorphisms and the risk of esophageal squamous cell carcinoma. Acta Oncol, 46, 1090-6. https://doi.org/10.1080/02841860701373595
  83. Yang Y, Qiao J, Li MZ (2010). Association of polymorphisms of interleukin-18 gene promoter region with polycystic ovary syndrome in chinese population. Reprod Biol Endocrinol, 8, 125. https://doi.org/10.1186/1477-7827-8-125
  84. Yao JC, Phan A, Hoff PM, et al (2008). Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol, 26, 1316-23. https://doi.org/10.1200/JCO.2007.13.6374
  85. Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G (2001). Interleukin-18 expression induced by Epstein-Barr virusinfected cells. J Leukoc Biol, 69, 779-84.
  86. Yao L, Zhang Y, Chen K, Hu X, Xu LX (2011). Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox. PLoS One, 6, 24684. https://doi.org/10.1371/journal.pone.0024684
  87. Ye ZB, Ma T, Li H, Jin XL, Xu HM (2007). Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol, 13, 1747-51. https://doi.org/10.3748/wjg.v13.i11.1747
  88. Yeh WL, Lu DY, Liou HC, Fu WM (2011). A forward loop between glioma and microglia: glioma-derived extracellular matrix-activated microglia secrete IL-18 to enhance the migration of glioma cells. J Cell Physiol.
  89. Yoneda S, Umemura T, Katsuyama Y, et al (2011) Association of serum cytokine levels with treatment response to pegylated interferon and ribavirintherapy in genotype 1 chronic hepatitis C patients. J Infect Dis, 203, 1087-95. https://doi.org/10.1093/infdis/jiq165
  90. Young-Ik Son, Ramsey MD, Robbie BM, et al (2001). Lotze Interleukin-18 (IL-18) Synergizes with IL-2 to Enhance Cytotoxicity, Interferon-g Production, and Expansion of Natural Killer Cells1. Cancer Res, 61, 884-8.
  91. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD (2010). IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol, 185, 4912-20. https://doi.org/10.4049/jimmunol.1002046
  92. Zhang Y, Li Y, Ma Y, et al (2011). Dual effects of interleukin-18: inhibiting hepatitis B virus replication in HepG2.2.15 cells and promoting hepatoma cells metastasis. Am J Physiol Gastrointest Liver Physiol, 301, 565-73. https://doi.org/10.1152/ajpgi.00058.2011

Cited by

  1. Interleukin-18 Synergism with Interleukin-2 in Cytotoxicity and NKG2D Expression of Human Natural Killer Cells vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7857
  2. Interleukin-37 Mediates the Antitumor Activity in Hepatocellular Carcinoma: Role for CD57+ NK Cells vol.4, pp.1, 2015, https://doi.org/10.1038/srep05177
  3. RETRACTED ARTICLE: Significance of Increased Serum Interleukin-18 Levels in Stroke Patients: A Meta-Analysis vol.52, pp.3, 2015, https://doi.org/10.1007/s12035-014-8977-1
  4. Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro vol.9, pp.4, 2015, https://doi.org/10.3892/etm.2015.2286